What is Kisspeptin-54?
Kisspeptin-54 is a reproductive-signaling peptide studied as an egg-maturation trigger during IVF. It is a distinct form from the shorter kisspeptin-10 already covered in this directory.
Biological role or research focus
Reproductive signaling and IVF research.
This was not a head-to-head comparison with a standard trigger. Clinical pregnancy is also different from a proven live-birth advantage.
Role reference: Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. · 2014 ↗
Names you may encounter
Kisspeptin · KP-54 · Metastin
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- KISS1-derived kisspeptin-54
- Research focus
- Reproductive signaling and IVF research
- Featured evidence
- Human dose-ranging study
- Source check
- October 4, 2026
Source: Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. · 2014 ↗
Quick answers
- Is Kisspeptin-54 FDA approved?
- No. No FDA-approved drug contains Kisspeptin-54. Source ↗
- Is Kisspeptin-54 safe?
- Kisspeptin-54 is an investigational reproductive hormone. Small, supervised IVF and hormone studies reported few problems, but they cannot establish long-term or pregnancy safety. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Kisspeptin-54 banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.1 Testosterone-stimulating peptides in males). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Kisspeptin-54 triggering of egg maturation (2014) | Human dose-ranging study | 53 women undergoing IVF. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human dose-ranging study · 2014
Kisspeptin-54 triggering of egg maturation
What did this publication test, and what did it find?
- Population / model
- 53 women undergoing IVF.
- Study design
- Dose-ranging administration of kisspeptin-54 after ovarian stimulation, with egg maturation, fertilization, and pregnancy follow-up.
- Main finding
- Egg maturation was observed, and fertilization with embryo transfer occurred in 49 of 53 participants. The study reported 12 clinical pregnancies.
- Limits & context
- This was not a head-to-head comparison with a standard trigger. Clinical pregnancy is also different from a proven live-birth advantage.
Source: Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. · 2014 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
29 registered studies name Kisspeptin-54 as an intervention; 5 are recruiting or under way, 0 have not started recruiting yet, 19 completed and 5 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism NCT04648969 · Stephanie B. Seminara, MD | Completed | Phase 2 | 2019-05-03 | 18 |
| Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea NCT07224438 · Stephanie B. Seminara, MD | Recruiting | Phase 2 | 2025-12-09 | 20 |
| Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease NCT07224490 · Stephanie B. Seminara, MD | Recruiting | Phase 1 | 2026-03-10 | 40 |
| Kisspeptin Administration Subcutaneously to Patients With IHH NCT05896293 · Stephanie B. Seminara, MD | Recruiting | Phase 2 | 2023-02-03 | 36 |
| Functional Proteins in Polycystic Ovary Syndrome NCT06793098 · Jagiellonian University | Recruiting | 2025-01-20 | 100 | |
| Recall by Genotype: Neuropeptide Stimulation NCT05901467 · Stephanie B. Seminara, MD | Terminated | Phase 1 | 2023-10-20 | 16 |
| Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test NCT04958109 · Massachusetts General Hospital | Completed | Phase 1 | 2021-10-28 | 16 |
| Dampening the Reproductive Axis With Continuous Kisspeptin NCT05971849 · Stephanie B. Seminara, MD | Completed | Phase 1 | 2023-10-06 | 8 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 29 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
GPR54 and kisspeptins. ↗
Results and problems in cell differentiation · 2008 · Journal Article, Research Support, Non-U.S. Gov't, Review
Kisspeptin-54 ameliorates chondrocyte senescence in osteoarthritis via SIRT3-mediated telomere protection and p53 acetylation inhibition. ↗
Neuropeptides · 2025 Dec · Journal Article
Kisspeptin-54 Restores Blood-Brain Barrier Integrity via GATA-4 in Ischemic Stroke. ↗
Chemical biology & drug design · 2025 Jun · Journal Article
Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. ↗
EBioMedicine · 2025 May · Journal Article, Randomized Controlled Trial
Read available full text ↗
Risks & interactions
Kisspeptin-54 is an investigational reproductive hormone. Small, supervised IVF and hormone studies reported few problems, but they cannot establish long-term or pregnancy safety.
Phase 2 IVF trials, including one in 60 women at high risk of ovarian hyperstimulation syndrome (none developed moderate or severe OHSS), and short hormone studies report few adverse events. Groups were small and closely supervised.
Unassessed: little human safety data
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Kisspeptin-54 triggers egg maturation in IVF (2014) ↗ · Kisspeptin-54 in women at high risk of OHSS (2015) ↗ · Intranasal kisspeptin and gonadotropin release in humans (2025) ↗
Safety & what remains unknown
Supervised IVF findings cannot establish safety or effectiveness of self-administered material, and the trial does not resolve uncommon reproductive risks.
Source: Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. · 2014 ↗
Evidence boundaries
This was not a head-to-head comparison with a standard trigger. Clinical pregnancy is also different from a proven live-birth advantage.
Source: Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. · 2014 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.1 Testosterone-stimulating peptides in males
Named ("kisspeptin and its agonist analogues"); prohibited in males. source
Other notes
- Only kisspeptin-10 appears on FDA's 503A category 2 list; kisspeptin-54 was not found on any category list. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
The featured publication concerns supervised IVF following controlled ovarian stimulation. It does not establish a general fertility supplement or interchangeable effects of all kisspeptin fragments.
Source: Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. · 2014 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Biology & proposed mechanism
Kisspeptin signaling stimulates the reproductive hormone pathway through its receptor and downstream GnRH/LH responses. The length and exact tested form matter when interpreting results.
Source: Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. · 2014 ↗
Questions worth asking
- Is this the same profile as Kisspeptin-10?
- What material, population, and route were actually studied?
- This was not a head-to-head comparison with a standard trigger. Clinical pregnancy is also different from a proven live-birth advantage.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is this the same profile as Kisspeptin-10?
No. Both belong to the kisspeptin family, but the featured trial used kisspeptin-54. Evidence should retain the tested form.
Source: Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. · 2014 ↗
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
Source: Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. · 2014 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
